PROCTER & GAMBLE HEALTH | GSK PHARMA | PROCTER & GAMBLE HEALTH/ GSK PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.6 | 68.3 | 50.7% | View Chart |
P/BV | x | 10.6 | 20.7 | 50.9% | View Chart |
Dividend Yield | % | 2.0 | 1.5 | 134.0% |
PROCTER & GAMBLE HEALTH GSK PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
GSK PHARMA Mar-23 |
PROCTER & GAMBLE HEALTH/ GSK PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 1,684 | 318.7% | |
Low | Rs | 3,883 | 1,231 | 315.5% | |
Sales per share (Unadj.) | Rs | 740.7 | 191.9 | 385.9% | |
Earnings per share (Unadj.) | Rs | 138.2 | 35.9 | 385.4% | |
Cash flow per share (Unadj.) | Rs | 155.2 | 39.8 | 390.3% | |
Dividends per share (Unadj.) | Rs | 95.00 | 32.00 | 296.9% | |
Avg Dividend yield | % | 2.1 | 2.2 | 93.6% | |
Book value per share (Unadj.) | Rs | 447.6 | 102.9 | 435.1% | |
Shares outstanding (eoy) | m | 16.60 | 169.41 | 9.8% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 7.6 | 82.2% | |
Avg P/E ratio | x | 33.5 | 40.6 | 82.3% | |
P/CF ratio (eoy) | x | 29.8 | 36.7 | 81.3% | |
Price / Book Value ratio | x | 10.3 | 14.2 | 72.9% | |
Dividend payout | % | 68.7 | 89.2 | 77.0% | |
Avg Mkt Cap | Rs m | 76,761 | 246,858 | 31.1% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,062 | 5,950 | 34.7% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 32,517 | 37.8% | |
Other income | Rs m | 184 | 1,007 | 18.3% | |
Total revenues | Rs m | 12,480 | 33,524 | 37.2% | |
Gross profit | Rs m | 3,247 | 8,033 | 40.4% | |
Depreciation | Rs m | 281 | 658 | 42.7% | |
Interest | Rs m | 8 | 18 | 42.5% | |
Profit before tax | Rs m | 3,142 | 8,364 | 37.6% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | 2,288 | 37.0% | |
Profit after tax | Rs m | 2,295 | 6,076 | 37.8% | |
Gross profit margin | % | 26.4 | 24.7 | 106.9% | |
Effective tax rate | % | 27.0 | 27.4 | 98.6% | |
Net profit margin | % | 18.7 | 18.7 | 99.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 24,943 | 47.0% | |
Current liabilities | Rs m | 6,791 | 13,264 | 51.2% | |
Net working cap to sales | % | 40.0 | 35.9 | 111.5% | |
Current ratio | x | 1.7 | 1.9 | 91.7% | |
Inventory Days | Days | 263 | 97 | 270.1% | |
Debtors Days | Days | 343 | 216 | 159.1% | |
Net fixed assets | Rs m | 10,617 | 6,988 | 151.9% | |
Share capital | Rs m | 166 | 1,694 | 9.8% | |
"Free" reserves | Rs m | 7,265 | 15,735 | 46.2% | |
Net worth | Rs m | 7,431 | 17,430 | 42.6% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 22,330 | 31,930 | 69.9% | |
Interest coverage | x | 409.1 | 462.6 | 88.4% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.6 | 1.0 | 54.1% | |
Return on assets | % | 10.3 | 19.1 | 54.0% | |
Return on equity | % | 30.9 | 34.9 | 88.6% | |
Return on capital | % | 42.4 | 48.1 | 88.1% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 13.1 | 48.1 | 27.2% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 1,605 | 15,630 | 10.3% | |
Fx inflow | Rs m | 1,465 | 1,622 | 90.4% | |
Fx outflow | Rs m | 1,605 | 15,630 | 10.3% | |
Net fx | Rs m | -140 | -14,008 | 1.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | 4,842 | 48.7% | |
From Investments | Rs m | -215 | 8,079 | -2.7% | |
From Financial Activity | Rs m | -985 | -15,433 | 6.4% | |
Net Cashflow | Rs m | 1,160 | -2,512 | -46.2% |
Indian Promoters | % | 0.0 | 0.0 | - | |
Foreign collaborators | % | 51.8 | 75.0 | 69.1% | |
Indian inst/Mut Fund | % | 20.0 | 11.4 | 175.5% | |
FIIs | % | 6.2 | 3.5 | 179.3% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 25.0 | 192.7% | |
Shareholders | 56,778 | 118,994 | 47.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare PROCTER & GAMBLE HEALTH With: DIVIS LABORATORIES CIPLA SUN PHARMA ZYDUS LIFESCIENCES DR. REDDYS LAB
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | GSK Pharma | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.43% | 3.26% | 0.45% |
1-Month | -1.15% | 10.82% | 2.55% |
1-Year | 0.73% | 72.80% | 56.14% |
3-Year CAGR | -8.76% | 13.09% | 15.22% |
5-Year CAGR | 4.97% | 10.63% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the GSK Pharma share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of GSK Pharma the stake stands at 75.0%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of GSK Pharma.
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 95.0 per share. This amounted to a Dividend Payout ratio of 68.7%.
GSK Pharma paid Rs 32.0, and its dividend payout ratio stood at 89.2%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of GSK Pharma.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.